Figure 2. Study schema: Patients received sunitinib 37.5 mg PO daily from weeks 1–4 and bevacizumab (Bev) 5 mg/kg intravenously on days 1, 15, and 29 of each 6-wk cycle.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.